Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099291 | 0.96 | EPHX2 (0.40) | P2RX7KDM4ELMNASMN1; SMN2EPHX2 | |
| SCHEMBL30116965 | 0.84 | P2RX7 (0.49) | P2RX7EPHX2 | |
| SCHEMBL30116984 | 0.83 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL30116961 | 0.80 | P2RX7 (0.47) | P2RX7EPHX2 | |
| SCHEMBL26099758 | 0.79 | CTSS (0.39) | P2RX7LMNASMN1; SMN2EPHX2CTSS | |
| SCHEMBL26101269 | 0.76 | HDAC3 (0.47) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL26100237 | 0.75 | CTSS (0.37) | LMNASMN1; SMN2EPHX2CTSS | |
| SCHEMBL30117005 | 0.75 | EPHX2 (0.40) | P2RX7EPHX2 | |
| SCHEMBL30116993 | 0.71 | MLYCD (0.51) | P2RX7KDM4ELMNA | |
| SCHEMBL30116981 | 0.71 | CYP3A4 (0.40) | P2RX7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | claimed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | P2RX7 81/4885KDM4E 2078/4885LMNA 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.